Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo links with Kitasato for vaccine R&D

This article was originally published in Scrip

Executive Summary

Daiichi Sankyohas struck an alliance with Japan's Kitasato Institute for the R&D, manufacturing and marketing of vaccines for infectious diseases. The tie-up, with a specialised research and commercialisation unit within the institute, will cover both prophylactic and therapeutic vaccines and may extend to collaborations with third parties. Kitasato has developed recombinant technology using the AIK-C measles strain and is also the only academic institute in Japan to operate a vaccine production facility. Daiichi Sankyo has just launched Sanofi-Aventis's paediatric Haemophilus influenzae type B vaccine ActHIB in Japan.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts